Deepcell
Latest round
- Series B
Last raised
- Jan 2022
Total raised
- $87M
Investors
- 9
About Deepcell
Deepcell, Inc.Founded in 2017, Deepcell, Inc. operates out of Menlo Park, US, focusing on single-cell analysis through its REM-I platform.Deepcell, Inc. is primarily focused on advancing single-cell analysis through its flagship product, the REM-I platform. This platform integrates label-free imaging, deep learning, and gentle sorting technologies to deliver comprehensive analysis of cell morphology, which is crucial for understanding cell phenotype and function. The REM-I platform is utilized by researchers in fields such as cancer research, developmental biology, and cell and gene therapy, enabling real-time characterization of single cells.Deepcell's revenue model centers on the sale of the REM-I platform and its associated consumables. Transactions are primarily conducted through direct sales to research institutions and commercial laboratories, allowing clients to purchase the REM-I instruments and necessary consumables for their studies.In January 2022, Deepcell, Inc. Future initiatives may include developing new products and expanding into additional markets, although specific products and timelines have not been disclosed.
Who invested in Deepcell
9 investors across 3 rounds
See all investors in Deepcell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Deepcell
Who invested in Deepcell?
Deepcell has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Deepcell raised?
Deepcell has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Deepcell last raise money?
Deepcell's most recent round on record is a Series B, in Jan 2022.
What does Deepcell do?
Deepcell is a biotechnology company.
Where is Deepcell headquartered?
Deepcell is headquartered in Menlo Park, US.
Which VCs invest in companies like Deepcell?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Deepcell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Deepcell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.